MediBuddy reported steady revenue growth and a marked reduction in losses for the financial year ended March 2025, driven by rising demand for digital healthcare services and tighter cost controls. Operating revenue rose to ₹724.6 crore in FY25, up 12.3% from ₹645.4 crore a year earlier, while the company narrowed its net loss significantly.
Core services drive revenue expansion
The bulk of MediBuddy’s FY25 revenue came from its core healthcare offerings—online and offline doctor consultations, medicine delivery, diagnostic testing, and elective and non‑elective surgeries—along with services linked to health insurance. These segments together contributed roughly ₹722 crore to operating income, with other operating receipts adding about ₹2.5 crore.
In addition to operating revenue, MediBuddy recorded ₹18.4 crore in non‑operating income, largely from interest on fixed deposits, investment gains and miscellaneous sources, taking total income for the year to nearly ₹743 crore. The diversified income mix reflects the company’s efforts to broaden revenue streams beyond platform transactions.
Cost control helps contain overall spending
Total expenses for FY25 were approximately ₹879 crore, broadly flat year‑on‑year despite business expansion. Procurement of materials and services remained the largest expense item at about ₹333 crore, accounting for nearly 38% of total costs.
Employee benefits rose modestly to ₹176.8 crore (about an 8% increase), which included roughly ₹6 crore in ESOP charges. Other notable outlays comprised safety and security costs of ₹42.5 crore, technology and IT infrastructure spending of ₹32.5 crore, and a combined ₹138.7 crore for advertising, legal and professional fees, depreciation and finance costs.
Losses narrow, margins improve
Improved revenue visibility together with disciplined spending permitted a substantial reduction in losses. MediBuddy’s net loss fell to about ₹137 crore in FY25 from ₹215.7 crore in FY24, a decline of roughly 37%. On a per‑rupee basis, the company spent about ₹1.21 for every rupee of income, indicating continued focus on efficiency while pursuing growth.
EBITDA losses also moderated: the EBITDA margin improved to -14.19% in FY25 from -25.67% a year earlier. Although EBITDA remained negative at around ₹103 crore, the narrowing gap points to meaningful progress toward operating profitability.
Balance sheet strength and funding
As of March 2025, MediBuddy reported current assets of ₹395.2 crore, including nearly ₹80 crore in cash and bank balances, providing a liquidity cushion to support technology investment, service expansion and strategic partnerships across India’s healthcare ecosystem.
Since inception, the company has raised over $190 million from a mix of domestic and international investors. This funding has underpinned platform scale‑up, entry into new service categories and pan‑India expansion.
Outlook and market position
Founded in 2013, MediBuddy has become a notable player in India’s healthtech sector. With accelerating digital adoption, greater health awareness and demand for convenient care access, the company is positioned to benefit from structural tailwinds in the Indian healthcare market.
The FY25 performance highlights MediBuddy’s emphasis on sustainable growth and operational discipline as it progresses toward long‑term profitability, keeping it under close watch among investors and industry observers.
